TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological SCC of the skin expressing (IHC) moderately or highly the EGFR (++ and +++, on a semi-quantitative scale).~* Locally advanced or metastatic SCC of the skin not suitable for local surgery with documented progression.~* Presence of at least one measurable target lesion by RECIST criteria.~* At least one lesion accessible to biopsies.~* ECOG Performance status \< 2.~* Life expectancy \> 3 months.~* Age \> 18 years.~* Normal hematological (Neutrophils \> 1.5x109 cells/l, platelets \> 100x109 cells/l), hepatic (bilirubin \< 1.5 times the upper limit of the normal range (ULN); alkaline phosphatase and transaminases \< 5 x UNL in case of hepatic metastases or \< 2.5 x UNL in absence of hepatic metastases) and renal (serum creatinine \< 150 micromol/L) functions.~* Written informed consent.~* In case of second tumor,excepted carcinoma of the cervix and adequately treated basal or squamous cell skin carcinoma, the possibility for including a patient may be discussed with the principal investigator.~Exclusion Criteria:~* Prior chemotherapy~* Prior radiotherapy \< 1 month.~* Prior therapy with agent targeting EGFR~* Unstable systemic diseases or active uncontrolled infections.~* Patients (male and female) not using effective contraception if of reproductive potential.~* Females pregnant or lactating. Women of child bearing potential must have a negative serum or urine pregnancy test prior to start each cycle of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cetuximab (Type: EXPERIMENTAL): cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of rheumatoid arthritis (RA) ≥ 3 months.~* Moderately to severely active rheumatoid arthritis.~* Participants who per investigator judgment were incomplete responders to at least 12 weeks of an adequate dose of continuous treatment with or who were intolerant of one or a combination of non-biologic disease modifying anti-rheumatic drugs (DMARDs).~Exclusion criteria:~* Participants \< 18 years of age.~* Past history of, or current, autoimmune or inflammatory systemic or localized joint disease(s) other than RA.~* History of juvenile idiopathic arthritis or arthritis onset prior to age 16.~* Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.~* Prior treatment with any biologic anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies.~* Treatment with prednisone \> 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization.~* New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors within 4 weeks prior to randomization, except for the use of low-dose acetylsalicylic acid for cardiovascular diseases.~* Use of parenteral glucocorticoids or intra-articular glucocorticoids injection within 4 weeks prior to randomization.~* Prior treatment with a Janus kinase (JAK) inhibitor (tofacitinib).~* New treatment or dose-adjustment to on-going medication for dyslipidemia, such as statin, within 6 weeks prior to randomization.~* Participation in any clinical research study evaluating another investigational drug or therapy within 5 half-lives or 60 days of first dose of study drug administration, whichever is longer.~* Participants with a history of malignancy other than adequately-treated carcinoma in-situ of the cervix, non-metastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization visit. Non-malignant lymphoproliferative disorders are also excluded.~* Participants with active tuberculosis or untreated latent tuberculosis infection.~* Pregnant or breast feeding women.~The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sarilumab 150 mg q2w (Type: EXPERIMENTAL): Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
- Sarilumab 200 mg q2w (Type: EXPERIMENTAL): Sarilumab 200 mg SC injection q2w for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 18 to 80 years inclusive~* Subjects with an Overall Disease Severity of 3 (moderate)~* Subjects with 3% - 10% treatable BSA (Body Surface Area) excluding scalp, face, groin, axillae and/or other intertriginous areas~* For concurrent medications, type and dose must have been stable for at least 3 months prior to study entry and not expected to change during the study. Subjects receiving treatment with beta-blockers or lithium, whose dose has been stable for at lest 6 months and who have shown no worsening of their psoriasis, may be included in the study, at the discretion of the investigator~Exclusion Criteria:~* Subjects with intakes of more than 2,000 IU/day (50 mcg/day) of vitamin D (tolerable upper intake level) and/or more than 1,000 mg/day of calcium~* Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas~* Subjects with a wash-out period for topical treatment less than 30 days (Any steroid containing medication, dovonex, anthralin, tar and/or UVB treatment)~* Subjects with a wash-out period for systemic treatment less than 12 weeks (corticosteroids, biologics and/or PUVA treatment; Examples of these therapies include, but are not limited to PUVA, Soriatane, Cyclosporine, Hydroxyurea, Mycophenolate mofetil, Sulfasalazine, Azathioprine, Alefacept, Efalizumab, Adalimumab, Etanercept, Infliximab, Rituximab, and Methotrexate)~* Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis~* Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1) Vectical™ Ointment and Clobex® Spray (Type: OTHER): Vectical™ Ointment weekdays \& Clobex® Spray weekends regimen
- 2) Clobex® Spray and Vectical™ Ointment (Type: OTHER): Clobex® Spray morning and Vectical™ Ointment evening regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A subject with a histologically or cytologically confirmed diagnosis of malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is applicable~* An archived tumor tissue is available or biopsy of tumor tissues can be newly performed~* A Japanese male or female, age greater than or equal to (\>=) 20 years~* A subject who has read the Subject Information Sheet and understood the details of this clinical trial, and is willing and able to give his/her informed consent.~* A female of child-bearing potential must have a negative blood pregnancy test result at her screening period. A female subject of child-bearing potential must be willing to avoid pregnancy by using an adequate method of contraception Life expectancy is at least 3 months~* Other inclusion criteria apply~Exclusion Criteria:~* Known Human immunodeficiency virus (HIV) positivity, active hepatitis C, or active hepatitis B~* Presence of liver fibrosis or liver cirrhosis that has been histologically diagnosed~* Signs or symptoms that suggest transmissible spongiform encephalopathy~* Received major surgery within 6 weeks before Day 1 in Cycle 1~* Known drug abuse or alcohol abuse~* Known hypersensitivity to any of the trial treatment ingredients~* Hematological test abnormalities~* Renal impairment as defined in the protocol~* Liver dysfunction as defined in the protocol~* History or presence of central nervous system metastasis~* History or presence of disease or condition that may hamper compliance or absorption of the investigational medicinal product (IMP) due to difficulty in swallowing or absorption~* Poor performance status of Eastern Cooperative Oncology Group Performance status (ECOG PS) \>= 2~* Received any anti-cancer therapy days Received extensive prior radiotherapy that irradiates more than 30 percent of bone marrow~* Received any radiotherapy within 4 weeks before Day 1 in Cycle 1~* Pregnancy and lactation period~* History of receiving treatment with any c-Met signaling pathway inhibitor~* Participation in another interventional clinical trial within the past 30 days from Day 1 in Cycle 1~* Other significant disease that in the Investigator's opinion would exclude the subject from the trial~* Legal incapacity or limited legal capacity~* Other exclusion criteria apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MSC2156119J (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Adherence to Control Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* established diagnosis of hypertension~* prescribed at least one blood pressure (BP) medication~* at least two consecutive clinic visits with elevated BP according to Joint National Committee (JNC-7) guidelines (i.e., BP ≥ 140/90 mmHg or ≥ 130/80 mmHg if diabetes or chronic kidney disease)~* 18 to 80 years old~* at least one prior visit with a clinician enrolled in the study~Exclusion criteria~* severe mental illness~* resided in a long-term care facility~* unable to use the electronic adherence device due to physical or cognitive impairment~* non-English or non-Spanish speaking~* unavailable for follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Concealment (control) (Type: OTHER): Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
- Disclosure (intervention) (Type: EXPERIMENTAL): Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis B Vaccination Among Drug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 18 and 70 years at the enrolment~* current illicit drug users before drug rehabilitation~* negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment~* having spent acute physiological detoxification phase~Exclusion Criteria:~* any intolerance or allergy to any component of the vaccine~* ongoing opportunistic infection~* liver disease~* hemopathy~* cancer~* unexplained fever in the last week before the recruiting

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
- 20 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
- Control (Type: NO_INTERVENTION): Receive no vaccination during the study period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identify as African American/Black, Hispanic (any race), or White non-Hispanic~* Smoke at least 5 cigarettes/day or carbon monoxide (CO) reading of at least 8 ppm~* be over age 18~* speak/read English and/or Spanish~Exclusion Criteria:~* Contraindications for transdermal nicotine patch therapy (TNP)~* Cognitive or mental health impairment that inhibits group treatment~* Currently being treated for smoking cessation, alcoholism, or illicit drug use~* Unable to attend sessions~* Indications that participant is not appropriate for the study (e.g., aggressive, intoxicated, disruptive, visibly ill)~* Does not self-identify as African American, Hispanic, or White (non-Hispanic)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group Cognitive Behavioral Therapy (Type: EXPERIMENTAL): Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) \[21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)\].
- General Health Education (Type: ACTIVE_COMPARATOR): Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) \[21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)\].

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Behavioral Treatments for Stress Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 25 to 60 years old~* Good general health~* Able to attend all 8 sessions of the course and practice the techniques each night for 25 minutes~Exclusion Criteria:~* Psychiatric medications~* Significant medical or psychological illness~* Metalic implants (such as a pacemaker or artificial joints) that are not MRI compatible.~* Claustrophobia~* Pregnancy~* Previous head trauma or neurological disorder~* Previous experience with yoga or meditation

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Program A - Relaxation Response (RR) (Type: ACTIVE_COMPARATOR): One of the 2 stress reduction courses
- Program B - Mindfullness-based stress reduction (MBSR) (Type: ACTIVE_COMPARATOR): One of the 2 stress reduction courses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged above 21 years old;~* Documented coronary artery disease by angiography and confirmed ischemia by myocardial perfusion scintigraphy with physical or pharmacological stress;~* Class IV angina pectoris (CCSAC) that is unresponsive to optimized dose of at least two anti-anginal medications including nitrates, beta blocker, calcium channel blocker or Ranolazine) as well as aspirin or other anti-platelet agent plus statin therapy;~* Considered to not be a candidate for either percutaneous catheter or surgical myocardial revascularization due to either anatomical type, extent of coronary disease in the target vessel, or caliber of the distal vessels;~* Ejection fraction of \> 45% by Transthoracic echocardiogram with Doppler by the Simpson method;~* Myocardial perfusion scintigraphy showing that the areas of myocardial ischemia supply viable tissue.~Exclusion Criteria:~* Significant Valvular Heart Disease;~* Chronic kidney disease requiring renal replacement therapy;~* Severe comorbidities associated with the reduction of life expectancy in less than 5 years;~* Ongoing abusive use of alcohol or illegal drugs (Based on the Diagnostic and Statistical Manual (DSM) IV - CAGE questionnaire);~* Positive Serologic test for HIV, Human T-cell lymphotrophic virus (HTLV), Hepatitis A, B and C;~* History of Malignant neoplasia in the last 2 years;~* Participation into other studies of cell therapy in the last year;~* Pregnancy or Breast-feeding.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stem Cell Therapy (Type: EXPERIMENTAL): All subjects enrolled in the study underwent:~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled for repair of their pectus excavatum with minimally invasive (MIRPE) placement of steel or titanium braces at Mayo Clinic Arizona~* Must be able to take oral medications preoperatively and postoperatively.~Exclusion Criteria:~* American Society of Anesthesiology class IV or higher~* Allergic to Ropivacaine or other local anesthetics~* NSAID allergy~* Specific epidural contraindication~* Currently using opioids, sedatives, or hypnotics~* Are pregnant as verified by preoperative pregnancy testing~* Inability to place an epidural, patient refusal for epidural, or failure of an epidural to be properly placed or maintain proper placement for adequate pain control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Thoracic epidural (Type: ACTIVE_COMPARATOR): Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
- ON-Q soaker catheter system (Type: EXPERIMENTAL): ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male healthy subjects with higher education level~Exclusion Criteria:~* do not understand Portuguese language~* obese patients (BMI \> 27 kg/m2)~* use of NSAID, steroids, analgesics, anticonvulsant drugs, as well as alpha and beta-blockers~* score ≥ 13 on Beck II Questionnaire~* sleep deprivation in the night before evaluation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group S-Ketamine (Type: EXPERIMENTAL): S-Ketamine will be diluted in normal saline and administrated in a target controlled infusion using an infusion pump to obtain a plasma target of 60 ng/ml according to Domino's model. Infusion will start during the interval between the 3rd and 4th blocks of the task.
- Group Placebo (Type: PLACEBO_COMPARATOR): A previously prepared identical solution containing only normal saline will be infused at the same infusion rates of group ketamine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete